Immunicum AB: Immunicum AB (publ) Announces Nomination Committee for AGM 2019
Press Release19 October 2018
Immunicum AB (publ) Announces Nomination Committee for AGM 2019Immunicum AB (publ) in accordance with the principles of appointing the
Nomination Committee, adopted by the Annual General Meeting of April 25,
2018, announced today that the members of the Nomination Committee have been
appointed. The Nomination Committee for Immunicum shall be appointed by the
four largest shareholders as of August 31, 2018 that have accepted the
invitation to participate in the committee.
The Chair of Immunicums Board, Michael Oredsson, has contacted major
shareholders in order to appoint a Nomination Committee.
The following members have been appointed by the four largest shareholders
that have accepted the invitation to participate in the Nomination Committee:
Martin Lindström, appointed by Loggen Invest AB, Chairman of the Nomination
Bengt Andersson, appointed by Bengt Andersson
Ivar Nordqvist, appointed by Ivar Nordqvist
Jamal el-Mosel, appointed by BISP Invest AB
In total, the Nomination Committee represents 9.2% of the total number of
shares and votes in the company.
The Annual General Meeting will be held on the 25th of April 2019 in
Information about the work of the Nomination Committee can be found at
Shareholders wishing to make proposals to the Nomination Committee should
submit their proposal in writing via email email@example.com by post
to Immunicum AB (publ), Att: Valberedningen, Grafiska Vägen 2, 412 63
For more information, please contact:Martin Lindström, Chairman of the Nomination Committee
Telefon: +46 (0) 70 36 86 515
Michael Oredsson, Chairman of the Board of Directors
Telephone: +46 70 718 89 30
About Immunicum AB (publ)Immunicum is establishing a unique immuno-oncology approach through the
development of allogeneic, off-the-shelf cell-based therapies. Our goal is to
improve survival outcomes and quality of life by priming the patients own
immune system to fight cancer. The companys lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the potential
to become a backbone component of modern cancer combination treatments in a
variety of solid tumor indications. Founded and based in Sweden, Immunicum is
publicly traded on the Nasdaq Stockholm www.immunicum.com
20181019_Immunicum AGM Nomination Committee_ENG_Final
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire